Mês: Janeiro 2026

Bedfont® Scientific Limited is pleased to support a major milestone to improve asthma care

Posted on

Intermedical UK proudly delivers the 3,000th NObreath® FeNO device to the UK market.

Bedfont® Scientific Limited, a medical device manufacturer based in Kent, with over 49 years’ experience in the breath analysis industry, was pleased to support its UK distributor, Intermedical UK, in supplying the 3,000th NObreath® Fractional exhaled Nitric Oxide (FeNO) device in the UK. Intermedical UK, a trusted leader in respiratory health, has been providing cardio-respiratory diagnostic and therapy equipment for frontline care since 1997.

Bedfont® support major milestone in asthma care. Bedfont Supports FeNO Milestone.
Bedfont® and Intermedical Team

Livio Gagliardi, Acting Managing Director at Intermedical (UK) Ltd, said, “Reaching the 3,000th NObreath® FeNO device in the UK is a shared success that reflects the dedication of both the Intermedical and Bedfont® teams. Together, we have worked hard to deliver a clinically proven, accessible, and cost-effective FeNO solution that genuinely meets the needs of frontline healthcare. We are incredibly grateful to our customers for placing their trust in us and for recognising the value that NObreath® brings to asthma diagnosis and ongoing management. Their commitment to improving respiratory care is what makes milestones like this possible, and we look forward to continuing this journey of innovation and impact alongside Bedfont®.”

NObreath FeNO device. Bedfont Supports FeNO Milestone.

The NObreath® FeNO device, manufactured by Bedfont®, is an innovative diagnostic tool that measures airway inflammation and helps healthcare professionals diagnose and manage asthma effectively. With over 3,000 devices now available across the UK, access to FeNO testing is improving, bringing Bedfont® closer to a world where everyone can access instant, non-invasive, and simple breath testing to support medical diagnosis.

As a valued long-term distributor of the NObreath®, Intermedical UK has played a key role in expanding access to high-quality respiratory diagnostics, and the close partnership over the years has been instrumental in reaching this monumental milestone.

Jason Smith, CEO at Bedfont®, comments, “This milestone of 3,000 devices in UK primary care highlights just how rapidly objective asthma testing is advancing. The updated joint UK guidelines now place even greater emphasis on FeNO, echoing the global shift toward evidence-based, accessible diagnostic tools. We are committed to making this technology available everywhere it is needed, ensuring clinicians and patients around the world benefit from fast, non-invasive breath testing.”

Bedfont® remains committed to improving asthma care worldwide, working closely with a global network of distributors to expand access to FeNO testing and improve asthma treatment. Recent partnerships in Mexico and India are already strengthening diagnostic capabilities, enabling clinicians in these regions to integrate simple, non-invasive breath testing into routine asthma assessment.

To learn more about Bedfont® and the NObreath® FeNO device, visit the website here.

coVita™ and Allergy Partners team up to improve asthma care in America

Posted on

Innovative NObreath® FeNO device is the allergists’ device of choice in the USA.

coVita™ LLC, a leader in advanced breath analysis and diagnostic solutions, serves as the U.S. distributor for the innovative NObreath® Fractional Exhaled Nitric Oxide (FeNO) device from UK-based Bedfont® Scientific Ltd. The new agreement with Allergy Partners marks the culmination of a strategic partnership developed over the past two years.

“The partnership established between coVita™ and Allergy Partners marks important progress in broadening access to FeNO technology on a global scale.” Said Jason Smith, CEO at Bedfont®. “We are pleased to support this collaboration and proud of the role coVita™ is playing in advancing high-quality asthma care.”

NObreath® device is allergists' device of choice in the USA.
Taking a FeNO test with the NObreath®

As the nation’s largest and most trusted integrated network of allergy and asthma specialists, Allergy Partners serves patients through more than 125 locations in over 20 states. Under the new agreement, all Allergy Partners clinics will provide FeNO testing with the NObreath® device, enhancing patient access to advanced, non-invasive tools that aid in asthma diagnosis and management. The NObreath® is the allergist’s device of choice in the USA, further underscoring its value in supporting accurate assessment and personalised treatment. With 26.8 million Americans, 8.2% of the U.S. population, affected by asthma in 2022, the need for innovative tools to support better care and disease management has never been greater.

“We are incredibly proud of our collaboration with Allergy Partners and thrilled to help them implement the NObreath® FeNO technology”, said Jason Aversano, CEO at coVita™.  “Their determination to integrate FeNO testing across their entire network of providers is illustrative of their understanding of the vital role objective FeNO monitoring plays in the modern clinical setting.”

Bedfont® Scientific, manufacturer of the NObreath®, and coVita™, share a long-standing partnership grounded in mutual respect, trust, and a shared vision to improve respiratory health through innovation. Over the years, the two companies have worked hand in hand to make advanced breath analysis more accessible to clinicians and patients throughout the United States. Their collaboration continues to exemplify how aligned values and global cooperation can drive meaningful change in healthcare.

To learn more about the NObreath® FeNO device, visit the website here.

References

  1. CDC. Most Recent Asthma Data [Internet]. Asthma Data. 2024. Available from: https://www.cdc.gov/asthma-data/about/most-recent-asthma-data.html

Bedfont® Scientific Limited is proud to exhibit cutting-edge breath analysis devices at WHX Dubai.

Posted on

Smokerlyzer®, Gastrolyzer®, and NObreath® devices on show at the world’s largest healthcare event.

Bedfont® Scientific, world leaders in breath analysis, with over 49 years of experience in the medical breath analysis industry, is thrilled to be showing its innovative devices at this year’s World Health Expo (WHX) Dubai, from the 9th to the 12th February 2026. Formally known as Arab Health, WHX Dubai has grown into a global healthcare hub, attracting professionals from over 180 countries. The event is due to take place at the Dubai Exhibition Centre.

Bedfont® exhibit at WHX Dubai
Bedfont Team at Arab Health 2025

WHX Dubai represents a cornerstone event for international healthcare collaboration, innovation, investment, and knowledge sharing. Bedfont® is pleased to be demonstrating its devices at the world’s largest healthcare event. On show at stand S7.F90.F, you will find the Smokerlyzer® range of breath carbon monoxide (CO) devices, which aid smoking cessation. The Gastrolyzer® hydrogen-methane breath testing (HMBT) range, which is used to help detect gastrointestinal disorders. And the NObreath® fractional exhaled nitric oxide (FeNO) device, which aids asthma diagnosis and management.

Jason Smith, CEO at Bedfont® Scientific, said, “WHX Dubai continues to set the benchmark for healthcare innovation worldwide. Our presence underscores our dedication to excellence and to delivering devices that genuinely elevate the standard of patient care. As healthcare demands grow, we remain committed to providing solutions that empower clinicians, improve outcomes, and support a more efficient, responsive care environment. We look forward to building on the momentum generated at this year’s event.”

WHX Dubai 2026 is expected to attract over 235,000 professionals, offering the opportunity to see innovative medical solutions, attend educational and thought-leadership conferences, and network with like-minded individuals looking to improve healthcare across the globe. With strong relationships already established across the Middle East, Bedfont® hopes to engage with various healthcare professionals during the event, showcasing its innovative breath analysis devices.

You will find the friendly Bedfont® team at stand S7.F90.F. For more information on Bedfont® and to learn more about the Smokerlyzer®, Gastrolyzer®, and NObreath® devices, visit the website here.

New year, new you: setting quit goals with carbon monoxide (CO) monitoring.

Posted on

January marks the start of a new year, with many people using this time as a fresh start and the perfect time to set health-improving goals. A study in 2024 found that January is the most popular month of the year for people to give up smoking, with an average of 440,670 online searches for terms related to quitting smoking1.

New Year’s resolutions can be health-focused or financially driven, and quitting smoking aligns perfectly with both. Not only does it improve overall health, but it also saves significant money, allowing people to achieve their financial goals.

Understanding CO monitoring.

Carbon monoxide is an odourless, colourless, and tasteless gas that is produced during incomplete combustion. This gas is found when smoking tobacco and has a profound effect on people’s health. When inhaled, CO binds to haemoglobin in red blood cells, reducing the delivery of oxygen throughout the body2. Smokers typically have high CO levels, and this can be monitored through a CO monitoring device used to aid a quit-smoking attempt.

The role of CO monitoring in quitting smoking.

A CO monitoring device, like the Smokerlyzer®, measures the levels of CO on exhaled breath, establishing a person’s smoking status. The device offers a simple test: the user exhales slowly into the device to receive an instant CO reading, providing tangible feedback. Using a CO monitoring device during a quit attempt empowers the user to take control of their own health and, by seeing their CO levels drop over time, motivates them to continue their quit attempt.

The Smokerlyzer® range.

  • Micro+™ – a CO breath and foetal %COHb %FCOHb device providing instant results, in parts per million (ppm), to help people stop smoking.
  • piCO™ – a breath CO device, providing instant results in exact ppm and %COHb to help people stop smoking.
  • piCObaby™ – a breath CO device for pregnant women to help them stop smoking, providing instant results in exact ppm, %COHb and %FCOHb.
  • iCOquit® – a personal CO device, which can be used at home to help you quit smoking.

Setting realistic quit goals.

Quitting smoking doesn’t happen instantly; it is a process, and like any significant lifestyle change, it works best when you set clear, achievable goals. A structured approach can help you stay focused, track progress, and celebrate success along the way. A helpful way to plan your quit journey is to make your goals SMART.

  • Specific – Be clear about what you want to achieve.
  • Measurable – Use CO readings or smoke-free days to track progress.
  • Achievable – Set goals that challenge you but are realistic.
  • Relevant – Focus on why quitting matters to you.
  • Time-bound – Set a timeframe for your targets.

Tracking progress and staying motivated.

Measuring CO levels during a quit attempt provides users with visual feedback; watching CO levels drop is a powerful motivator that helps people continue their journey. CO monitoring is also helpful in identifying relapses early and prompting users to get back on track. Quitting smoking is notoriously difficult, and it is important to celebrate milestones during a quit journey. Lower CO readings and smoke-free days are worth celebrating.

January provides the perfect opportunity to make positive, lasting changes, and quitting smoking is one of the most powerful steps you can take for your health. CO monitoring allows you to see tangible proof of your progress from the very first days of your quit journey. Watching CO levels drop is a reminder that your lungs are healing, your oxygen levels are improving, and your body is recovering.

Whether you are cutting down gradually or quitting altogether, setting clear goals, tracking your results, and celebrating each milestone can keep you motivated and on track. For more information on the Smokerlyzer® range and how it can aid a quit-smoking attempt, visit the website here.

References

  1. Leah. New study reveals the most popular times of year to quit smoking – Digital Health Technology News [Internet]. Digital Health Technology News. 2024 [cited 2025 Nov 6]. Available from: https://www.healthtechdigital.com/new-study-reveals-the-most-popular-times-of-year-to-quit-smoking/
  2. Cancer Research UK. What’s in a cigarette? [Internet]. Cancer Research UK. CRUK; 2023. Available from: https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/smoking-and-cancer/whats-in-a-cigarette-0
Back to top